Antinuclear Antibody (ANA) Testing Industry Analysis 2018: Market Top Key Players Are Merck KGaA, Bio-Rad Laboratories, Trinity Biotech, Antibodies Inc., EUROIMMUN AG, And Immuno Concepts Among Others

Antinuclear antibody test is a sensitive screening test used to diagnose autoimmune disorders. It is used to detect the presence of autoimmune disorders that affect tissues and organs in the body. These tests detect the presence of antinuclear antibodies in the blood serum. The test is used in symptoms such as low-grade fever, skin sensitivity to light, persistent fatigue, weakness and inflammation, and damage to organs and tissues.

Avail 10% Discount on Direct Purchase Or kindly send the email at sopan.gedam@databridgemarketresearch.com

Global Anti-Nuclear Antibody Test Market is expected to reach USD 1,964.47 million by 2025 from USD 1,093.40 million in 2017, at a CAGR of 7.7% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Here is the Solution! Click Here For Free Sample Report @: http://databridgemarketresearch.com/request-a-sample/?dbmr=global-antinuclear-antibody-test-market

Antinuclear Antibody Test Market Analysis Report contains all Analytical and Statistical brief about Market Overview, Growth, Demand and Forecast Research. This Antinuclear Antibody Test Market report offers some searching overview and solution in the complex world of Antinuclear Antibody Test Industry.

Top Companies Analysis:

The global anti-nuclear antibody test market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. In 2017, the global anti-nuclear antibody test market is dominated by Alere, Inc., followed by Bio-Rad Laboratories and Thermo Fisher Scientific, Inc. Other players in this market include are Trinity Biotech, Antibodies Inc., EUROIMMUN AG, and Immuno Concepts among others.

ALERE, INC.:

Founded in 2001 and headquartered in Massachusetts, U.S. Alere Inc. operates in rapid diagnostics tests devices. Alere segments are focused on cardiometabolic, infectious disease, and toxicology testing. Alere Inc. offers wide range of diagnostic tests for cardiometabolic disease, and toxicology in the United States and across the globe.

The products offered by the company includes rapid diagnostic test systems for diagnosis of point-of-care analyzers and test cassette systems for the blood cholesterol, glucose, and related lipids tests and over-the-counter tests for cholesterol monitoring; blood analysis systems for blood gas, electrolyte, and metabolite testing. The anti-nuclear antibody test products are offered by the test and instruments categories.

Abbott Laboratories acquired Alere which has significantly expanded Abbott’s global diagnostics presence. Alere is operating as a subsidiary of Abbott Laboratories.

BIO-RAD LABORATORIES:

Bio-Rad Laboratories, Inc. founded in 1952 and headquartered in California, U.S. It is engaged in development and production of specialty chemicals used in biochemical, pharmaceutical and other life science research applications. It operates its business through its two business segments life science and clinical diagnostics.

Life Science segment offers the wide range of instruments, software, consumables, reagents, and content for the growing fields of cell biology, gene expression, protein purification, protein quantitation, drug discovery and manufacture, food safety, and science education.

Clinical Diagnostics offers the wide range of innovative products to clinical laboratories worldwide. It has its global presence in over 35 countries.

Any Specific Requirements? Questions? Ask to Our Industry Expert @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-antinuclear-antibody-test-market

Drivers: Global Anti-Nuclear Antibody Test Market
The major factors driving the growth of this market are increasing incidence of autoimmune diseases, rising medical insurance, and rise in government healthcare protection.

INCREASING INCIDENCE OF AUTOIMMUNE DISEASES

The autoimmune diseases are the diseases in which immune system attacks healthy cells. Autoimmune diseases includes rheumatoid arthritis, lupus, celiac disease, Sjögren’s syndrome, polymyalgia rheumatic, multiple sclerosis, ankylosing spondylitis, alopecia areata, temporal arteritis and others. The antinuclear antibodies tests are used to diagnose these autoimmune diseases as these are high-morbidity and moderate-mortality chronic conditions.

The increasing number of autoimmune diseases requires more number of ANA tests to be performed for the diagnosis. With the rising number of diagnostic tests, demand of ANA test kits and other products are also increasing which is ultimately boosting the market to grow.

RISING MEDICAL INSURANCE

The fittest folks may only need a primary care physician, but a person with autoimmune disorders may need an entire team of specialists along with health insurance payer. The causes of autoimmune disorders such as lupus, diabetes (type 1), rheumatoid arthritis, and Sjogren’s syndrome have not been determined, but an abnormal immune response is the common feature. Due to the chronic nature of these disorders, the financial cost to both patients and insurers is often high.

Medical or life insurance with an autoimmune disease can either be relatively easy or difficult completely depends on the severity of the condition and significant medical disclosures. The some insurance providers will provide immediate decisions of policy for the conditions such as Multiple Sclerosis. Some autoimmune diseases are accepted at normal terms by insurance providers whereas serious conditions are accepted at higher prices or declined altogether.

As per the Congressional Budget Office (CBO) and Joint Committee on Taxation (JCT), the enactment of the Patients Protection and Affordable Care Act (PPACA) will increase the share of patient aged below 65 years with insurance from 80.0% in 2012 to 89.0% by 2022, in U.S.

Health insurance coverage for autoimmune diseases in Europe has also increased. According to the Association of British Insurers, in 2015, approximately 5.1 million people were covered under private insurance in the U.K..Various initiatives taken by government to promote the diagnosis of autoimmune diseases are helping to grow the ANA testing products market

RISE IN GOVERNMENT HEALTHCARE PROTECTION

In February 2014, National Institutes of Health (NIH), biopharmaceutical companies, and multiple non-profit organizations launched first-time new public-private partnership to identify and validate the most capable biological targets for therapeutics. Foundation for the NIH (FNIH) managed the Accelerating Medicines Partnership (AMP) that brought high-level government, industry and non-profit foundation partners together to design the research plan for the autoimmune diseases of rheumatoid arthritis and systemic lupus erythematosus (lupus).

Purchase Full Report @ http://databridgemarketresearch.com/reports/global-antinuclear-antibody-test-market/

Related Report

Global Molecular Spectroscopy Market – Industry Trends and Forecast to 2024

Global Molecular Spectroscopy Market, By Type (Nuclear Magnetic Resonance (Continuous Wave, Fourier Transform, Solid State), UV-Vis, Infrared (IR), Near Infrared (NIR), Colour Spectroscopy, Raman Spectroscopy, Others), By Applications (Pharmaceuticals, Biotech, Food and Beverages, Environmental Testing, Academics, Others), By Geography (North America, South America, Europe, Asia-Pacific, Rest of the World) – Industry Trends and Forecast to 2024

http://databridgemarketresearch.com/reports/global-molecular-spectroscopy-market/

About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.